State Street Corp Purchases 55,480 Shares of Aratana Therapeutics, Inc. (PETX)

State Street Corp raised its position in shares of Aratana Therapeutics, Inc. (NASDAQ:PETX) by 10.2% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 597,180 shares of the biopharmaceutical company’s stock after acquiring an additional 55,480 shares during the period. State Street Corp owned approximately 1.39% of Aratana Therapeutics worth $4,317,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Janney Montgomery Scott LLC raised its holdings in shares of Aratana Therapeutics by 7.9% during the 2nd quarter. Janney Montgomery Scott LLC now owns 16,400 shares of the biopharmaceutical company’s stock worth $119,000 after acquiring an additional 1,200 shares in the last quarter. Voya Investment Management LLC raised its holdings in shares of Aratana Therapeutics by 22.7% during the 2nd quarter. Voya Investment Management LLC now owns 19,530 shares of the biopharmaceutical company’s stock worth $141,000 after acquiring an additional 3,610 shares in the last quarter. American International Group Inc. raised its holdings in shares of Aratana Therapeutics by 7.1% during the 1st quarter. American International Group Inc. now owns 20,534 shares of the biopharmaceutical company’s stock worth $109,000 after acquiring an additional 1,354 shares in the last quarter. Ray Gerald L & Associates Ltd. raised its holdings in shares of Aratana Therapeutics by 0.8% during the 2nd quarter. Ray Gerald L & Associates Ltd. now owns 24,100 shares of the biopharmaceutical company’s stock worth $174,000 after acquiring an additional 200 shares in the last quarter. Finally, ProShare Advisors LLC raised its holdings in shares of Aratana Therapeutics by 7.2% during the 2nd quarter. ProShare Advisors LLC now owns 25,322 shares of the biopharmaceutical company’s stock worth $183,000 after acquiring an additional 1,709 shares in the last quarter. 73.95% of the stock is currently owned by institutional investors and hedge funds.

Several analysts have recently issued reports on the company. Zacks Investment Research cut Aratana Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, November 18th. HC Wainwright assumed coverage on Aratana Therapeutics in a report on Friday, November 17th. They set a “buy” rating and a $10.00 price objective on the stock. Jefferies Group set a $9.00 price objective on Aratana Therapeutics and gave the stock a “buy” rating in a report on Thursday, November 16th. ValuEngine cut Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Finally, Lake Street Capital decreased their price objective on Aratana Therapeutics from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, August 25th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $8.75.

Aratana Therapeutics, Inc. (NASDAQ:PETX) opened at $5.43 on Friday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.08 and a current ratio of 3.42. Aratana Therapeutics, Inc. has a 12-month low of $4.97 and a 12-month high of $8.63.

Aratana Therapeutics (NASDAQ:PETX) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.24) by $0.03. The firm had revenue of $6.16 million for the quarter, compared to the consensus estimate of $6.47 million. Aratana Therapeutics had a negative return on equity of 48.79% and a negative net margin of 358.55%. The company’s revenue for the quarter was up 1440.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.38) EPS. equities research analysts anticipate that Aratana Therapeutics, Inc. will post -1.03 earnings per share for the current year.

In other news, COO Brent Standridge sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $6.11, for a total transaction of $61,100.00. Following the transaction, the chief operating officer now owns 70,267 shares of the company’s stock, valued at approximately $429,331.37. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Peter Steven St sold 50,000 shares of the business’s stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $7.00, for a total value of $350,000.00. Following the transaction, the insider now directly owns 529,359 shares in the company, valued at approximately $3,705,513. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,127,032 shares of company stock worth $6,622,391. Corporate insiders own 5.20% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This article was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at https://www.dispatchtribunal.com/2017/12/08/state-street-corp-purchases-55480-shares-of-aratana-therapeutics-inc-petx.html.

About Aratana Therapeutics

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Institutional Ownership by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply